12:17:47 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaSmall Cap Stockholm
IRRAS är ett medicinbolag inriktade mot att utveckla lösningar för underlättande av kirurgiska ingrepp vid hjärnsjukdomar. Idag har bolaget utvecklat en teknologisk plattform som fokuserar på att förbättra en rad olika delbehandlingar vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Utöver ämnar bolaget att förbättra tillförandet av läkemedel i behandlingarna. Bolaget har sitt huvudkontor i Stockholm.


2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 Ordinarie utdelning IRRAS 0.00 SEK
2018-06-01 Årsstämma 2018
2018-05-29 Kvartalsrapport 2018-Q1
2018-02-21 Bokslutskommuniké 2017
2017-11-13 Kvartalsrapport 2017-Q3
2021-01-12 08:00:00
  • Collaboration agreement with Neurosurgery Department of Karolinska University Hospital will further enhance the usage of the company's transformative IRRAflow system to benefit neurocritical care patients in Sweden
  • Karolinska University Hospital is one of Scandinavia's premier health facilities and one of Europe's largest teaching hospitals  

Stockholm, January 12, 2021 - IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced a collaboration agreement with Karolinska University Hospital, a world-class clinical facility, that includes the initiation of an evaluation of IRRAflow, the company's lead commercial product.

Peter Alpkvist, Neurosurgeon and head of Neurosurgical Intensive Care Unit (NICU) at Karolinska University Hospital, comments, "We are excited to bring an innovative, next-generation solution for the treatment of intracranial bleeding to our neurocritical care patients."

"We are pleased and excited to have this collaboration agreement executed and look forward to having the world's first irrigating ventricular drainage system available to the clinical team at the neurosurgery department of Karolinska University Hospital," said Coenraad Tamse, Vice President of International Sales at IRRAS.

"This partnership allows us to accelerate commercial launches in the Nordic region while working closely with a leading facility and clinical experts," added Edmond Malek, IRRAS' Nordic Country Sales Head.

About Karolinska University Hospital

Karolinska University Hospital is one of Scandinavia's premier health facilities and one of Europe's largest teaching hospitals. Their services encompass health care for disorders ranging from major public health diseases to rare medical conditions. In the Stockholm region, they are a designated provider of highly specialized medical services. Karolinska University Hospital also serve many patients from other parts of Sweden and from other countries around the world. As the county council's teaching hospital, Karolinska University Hospital has a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs in Sweden. They believe that patient care, research, and education must all play equally strong roles in its effort to extend and enhance people's lives. As a major teaching hospital they educate and train tomorrow's medical specialists and healthcare professionals.


IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:


Kleanthis G. Xanthopoulos, Ph.D.


Sabina Berlin
+46 73 951 95 02

The information was released for public disclosure, through the agency of the contact person above, on January 12, 2021 at 08:00 (CET).